Mendes-Bastos Pedro, Lazaridou Elisavet, Torres Tiago, Aggelakopoulos Charalampos, Katsantonis Ioannis, Aronis Pantelis, Rigopoulos Dimitrios, Azevedo Filomena, Santiago Felicidade, Papakonstantis Markos, Varela Paulo, Ribeiro Vera S G, Kollia Aikaterini, Papadavid Evaggelia
Dermatology Center, Hospital CUF Descobertas, R. Mário Botas, 1998-018, Lisboa, Portugal.
2nd Department of Dermatology-Venereology, Aristotle University School of Medicine, "Papageorgiou" General Hospital, Agiou Pavlou 76, Ag. Pavlos 564 29, Thessaloniki, Greece.
Dermatol Ther (Heidelb). 2025 Jun;15(6):1487-1505. doi: 10.1007/s13555-025-01414-1. Epub 2025 Apr 26.
Despite significant progress observed in the treatment of atopic dermatitis (AD), a considerable number of patients with severe disease are undertreated and have inadequate symptom control. This may be due to several reasons, such as underestimation of the implications of the disease on patients, families, and society, as well as inconsistent access to effective treatment. The multidimensional disease burden of AD includes other atopic comorbidities, sleep disturbance, and functional impairment and secondary consequences, including neuropsychiatric issues (anxiety and depression) and reduced health-related quality of life.
MEASURE-AD was a global, cross-sectional observational study in adolescents and adults with moderate-to-severe AD, conducted to describe disease burden, treatment patterns, and healthcare resource utilization.
The results concerning patients from Portugal and Greece indicate moderate-to-severe disease for most of the population with frequent disease flares. The quality of life of both adolescents and adults was greatly affected, mainly owing to itch. One out of five patients perceived that their treatment was not effectively controlling AD. Disease resulted in important out-of-pocket expenses and loss of productivity.
Understanding and recognizing the complex burden of moderate-to-severe AD is required to encourage and guide changes in public policy for the effective management of patients.
尽管在特应性皮炎（AD）的治疗方面取得了显著进展，但仍有相当数量的重症患者未得到充分治疗，症状控制不佳。这可能是由于多种原因造成的，比如对该疾病对患者、家庭和社会影响的低估，以及获得有效治疗的机会不一致。AD的多维疾病负担包括其他特应性合并症、睡眠障碍、功能损害以及继发性后果，包括神经精神问题（焦虑和抑郁）以及健康相关生活质量下降。
MEASURE-AD是一项针对中重度AD青少年和成人的全球性横断面观察性研究，旨在描述疾病负担、治疗模式和医疗资源利用情况。
来自葡萄牙和希腊患者的结果表明，大多数人群患有中重度疾病，疾病频繁发作。青少年和成人的生活质量均受到极大影响，主要原因是瘙痒。五分之一的患者认为他们的治疗未能有效控制AD。疾病导致了重要的自付费用和生产力损失。
需要理解和认识中重度AD的复杂负担，以鼓励并指导公共政策的变革，从而有效管理患者。
